Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 46,696 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 46,696 shares of the business’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $5.96, for a total value of $278,308.16. Following the completion of the sale, the insider owned 14,664,939 shares in the company, valued at approximately $87,403,036.44. The trade was a 0.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $401,738.15.
• On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.99, for a total value of $924,754.17.
• On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total value of $887,235.90.
• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.30, for a total value of $690,952.50.
• On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.20, for a total value of $1,367,317.00.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total value of $78,348.40.
• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.07, for a total value of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.08, for a total value of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.14, for a total value of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $2,820,764.10.

Vir Biotechnology Stock Performance

NASDAQ:VIR opened at $6.43 on Wednesday. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $14.45. The firm has a market cap of $893.23 million, a price-to-earnings ratio of -1.61 and a beta of 1.27. The business’s fifty day moving average is $5.40 and its 200 day moving average is $5.30.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The company had revenue of $1.21 million for the quarter, compared to the consensus estimate of $2.38 million. During the same quarter in the previous year, the firm posted ($1.02) earnings per share. The business’s revenue for the quarter was down 60.5% compared to the same quarter last year. Equities analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in Vir Biotechnology during the second quarter worth about $35,000. GAMMA Investing LLC boosted its holdings in shares of Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock worth $46,000 after purchasing an additional 5,972 shares in the last quarter. Apollon Wealth Management LLC purchased a new position in shares of Vir Biotechnology in the 2nd quarter worth about $50,000. Daiwa Securities Group Inc. boosted its holdings in shares of Vir Biotechnology by 2,200.6% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock worth $62,000 after purchasing an additional 11,773 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Vir Biotechnology in the 2nd quarter worth about $63,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on VIR shares. Raymond James Financial started coverage on Vir Biotechnology in a research note on Friday, July 11th. They set an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a research note on Monday, September 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Tuesday, October 14th. Bank of America upgraded Vir Biotechnology from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. Finally, Evercore ISI assumed coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 target price for the company. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).